Posted on 09/12/2009 in Medical Company Restructures Genzyme revealed this week that a new member has been elected to its board of directors.
Robert Bertolini was executive vice-president and chief financial officer at Schering-Plough until its recent merger with Merck Sharpe and Dohme.
He joined Schering-Plough in 2003, where he formed part of the team that was behind the strategic decisions that caused the organisation's adjusted net sales to rise from $8.6 billion (5.2 billion pounds) in 2004 to $20.8 billion in 2008.
However, he has now moved on to fill his new position at Genzyme.
Henri Termeer, Genzyme's chairman and chief executive officer, commented: "Bob brings to our board exceptionally strong industry and financial expertise, having worked with the pharmaceutical and health care industry for more than 25 years."
In other Genzyme news, the firm informed the European Medicines Agency in August that shortages of its Gaucher disease drug cerezyme (imiglucerase) were more serious than it initially believed.Other news stories from 09/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
